

Table 2: Subgroup Analyses for oral oseltamivir within 48 hours or after 48 hours

Outcome	Confirmed influenza	Age	Baseline risk (e.g. immunocompromised)	Dosage of antiviral	Type of Influenza A/B	Pandemic vs Seasonal	Severity of Influenza	Setting	Funding
Mortality	Confirmed 0.67 (0.25, 1.76) Unconfirmed 0.03 (0.00, 0.21) p = 0.005	-	Interaction among <i>low risk population</i> OR 1.47 (0.87, 2.50) <i>immunocompromised</i> OR 0.16 (0.02, 1.34) <i>pregnant women</i> OR 0.03 (0, 0.21)	Interaction between <i>standard dose</i> OR 0.32 (0.07, 1.41) <i>300 mg/daily (also ICU setting)</i> OR 1.76 (0.94, 3.29)	-	-	-	NS	-
Hospitalization	NS	-	NS	-	-	-	-	-	-
ICU admissions	NS	-	NS	-	-	-	-	NS	-
Duration of hospitalization	-	-	-	-	-	-	-	-	-
Alleviation symptoms	-	-	-	-	-	-	-	-	-
Complications	-	-	-	-	-	-	-	-	-

“-“ indicates insufficient data from studies to conduct subgroup analyses; NS indicates non significant interaction